Vanguard Health Systems
The 10-second takeaway
For the quarter ended Dec. 31 (Q2), Vanguard Health Systems met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Vanguard Health Systems logged revenue of $1.51 billion. The 13 analysts polled by S&P Capital IQ anticipated a top line of $1.53 billion on the same basis. GAAP reported sales were 4.0% higher than the prior-year quarter's $1.61 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.15. The 14 earnings estimates compiled by S&P Capital IQ anticipated $0.17 per share. GAAP EPS of $0.14 for Q2 were 18% lower than the prior-year quarter's $0.17 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 26.6%, 650 basis points worse than the prior-year quarter. Operating margin was 4.0%, 10 basis points worse than the prior-year quarter. Net margin was 0.7%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.59 billion. On the bottom line, the average EPS estimate is $0.25.
Next year's average estimate for revenue is $6.16 billion. The average EPS estimate is $0.81.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vanguard Health Systems is outperform, with an average price target of $14.04.
Is Vanguard Health Systems the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Vanguard Health Systems to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.